Somatuline Depot Approval History

  • FDA approved: Yes (First approved August 30th, 2007)
  • Brand name: Somatuline Depot
  • Generic name: lanreotide acetate
  • Company: Ipsen Biopharmaceuticals, Inc.
  • Treatment for: Acromegaly

Somatuline Depot (lanreotide) is a long acting somatostatin analogue indicated for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors.

FDA Approval History for Somatuline Depot

DateArticle
Dec 16, 2014Approval FDA Approves Somatuline Depot (lanreotide) for Gastroenteropancreatic Neuroendocrine Tumors
Aug 31, 2007Approval Ipsen: Somatuline Depot Receives Marketing Approval in the United States for the Treatment of Acromegaly
Jan 15, 2007FDA Accepts for Filing a New Drug Application (NDA) for Somatuline Autogel
Nov  2, 2006Tercica Reports Somatuline Autogel NDA for Acromegaly Submitted to FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web4)